SPR (sepiapterin reductase) catalyzes the final step in tetrahydrobiopterin (BH4) biosynthesis, a critical cofactor for neurotransmitter production 1. BH4 is essential for the synthesis of serotonin, dopamine, epinephrine, norepinephrine, and nitric oxide 2. The enzyme functions downstream of GTP cyclohydrolase 1 (GCH1), the rate-limiting enzyme in BH4 synthesis 1. SPR activity becomes particularly important in pathological conditions where BH4 levels are abnormally elevated, such as in chr2 pain states following nerve injury 1. Unlike complete inhibition of GCH1 which blocks all BH4 production and affects physiological function, targeting SPR allows reduction of pathological BH4 production while maintaining some physiological BH4 synthesis 1. SPR deficiency causes DOPA-responsive dystonia, highlighting its clinical significance in neurological disorders. The enzyme has emerged as a therapeutic target for chr2 pain management, with inhibitors like sulfasalazine showing analgesic properties by reducing excess BH4 levels 2. Sepiapterin, which accumulates only when SPR is inhibited, serves as a reliable biomarker for target engagement in therapeutic applications 1.